Apollomics, Inc. – NASDAQ:APLM
Apollomics stock price today
$5.35
-4.53
-45.85%
Financial Health
0
1
2
3
4
5
6
7
8
9
Market closed
Open in about 12 hours
Apollomics stock price monthly change
+4951.13%
month
Apollomics stock price quarterly change
+4951.13%
quarter
Apollomics stock price yearly change
+1029.14%
year
Apollomics key metrics
Market Cap | 10.47M |
Enterprise value | N/A |
P/E | N/A |
EV/Sales | N/A |
EV/EBITDA | N/A |
Price/Sales | N/A |
Price/Book | N/A |
PEG ratio | N/A |
EPS | N/A |
Revenue | N/A |
EBITDA | N/A |
Income | N/A |
Revenue Q/Q | N/A |
Revenue Y/Y | N/A |
Profit margin | 0% |
Oper. margin | 0% |
Gross margin | 0% |
EBIT margin | 0% |
EBITDA margin | N/A |
Sign up &
create your own Smart Feed
create your own Smart Feed
Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.
Sign up for freeApollomics stock price history
Apollomics stock forecast
Apollomics financial statements
| 2020 | 1.83M | -74.82M | -4070.73% |
|---|---|---|---|
| 2021 | 0 | -94.79M | |
| 2022 | 0 | -240.81M | |
| 2023 | 821K | -172.60M | -21023.26% |
| 2025 | 1M | -94.7M | -9470% |
|---|---|---|---|
| 2026 | 0 | -145.3M |
Analysts Price target
Financials & Ratios estimates
| Jun 2022 | 99519000 | 312.00M | 313.51% |
|---|---|---|---|
| Dec 2022 | 76475000 | 524.59M | 685.97% |
| Jun 2023 | 71378000 | 15.68M | 21.97% |
| Dec 2023 | 55387000 | 14.15M | 25.55% |
| 2020 | -35.68M | 2.32M | 125.51M |
|---|---|---|---|
| 2021 | -43.31M | -38.95M | -1.64M |
| 2022 | -42.82M | 29.05M | -294K |
| 2023 | -43.20M | 21.36M | 21.22M |
Apollomics alternative data
| Dec 2023 | 43 |
|---|---|
| Jan 2024 | 43 |
| Feb 2024 | 43 |
| Mar 2024 | 43 |
| Apr 2024 | 43 |
| May 2024 | 45 |
| Jun 2024 | 45 |
| Jul 2024 | 45 |
Apollomics other data
| Quarter | Transcript |
|---|---|
| Q4 2023 28 Mar 2024 | Q4 2023 Earnings Call Transcript |
-
What's the price of Apollomics stock today?
One share of Apollomics stock can currently be purchased for approximately $5.35.
-
When is Apollomics's next earnings date?
Unfortunately, Apollomics's (APLM) next earnings date is currently unknown.
-
Does Apollomics pay dividends?
No, Apollomics does not pay dividends.
-
How much money does Apollomics make?
Apollomics has a market capitalization of 10.47M.
-
What is Apollomics's stock symbol?
Apollomics, Inc. is traded on the NASDAQ under the ticker symbol "APLM".
-
What is Apollomics's primary industry?
Company operates in the Healthcare sector and Biotechnology industry.
-
How do i buy shares of Apollomics?
Shares of Apollomics can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
-
How many employees does Apollomics have?
As Jul 2024, Apollomics employs 45 workers, which is 5% more then previous quarter.
-
When Apollomics went public?
Apollomics, Inc. is publicly traded company for more then 3 years since IPO on 26 Nov 2021.
-
What is Apollomics's official website?
The official website for Apollomics is apollomicsinc.com.
-
Where are Apollomics's headquarters?
Apollomics is headquartered at 989 East Hillsdale Blvd, Foster City, CA.
-
How can i contact Apollomics?
Apollomics's mailing address is 989 East Hillsdale Blvd, Foster City, CA and company can be reached via phone at +65 02094055.
Apollomics company profile:
Apollomics, Inc.
apollomicsinc.comExchange:
NASDAQ
Full time employees:
45
Industry:
Biotechnology
Sector:
Healthcare
Apollomics, Inc., a biotechnology company, engages in the discovery and development of oncology therapies to address unmet medical needs in California, Hangzhou, Shanghai, China, and Australia. It develops APL-101 (Vebreltinib), a potent, selective c-Met inhibitor for the treatment of non-small cell lung cancer and other advanced tumors; APL-102 is an oral active, small molecule multiple tyrosine kinase inhibitor for liver cancer, breast cancer, and esophageal cancer; and APL-122, a tumor inhibitor candidate to treat cancers within the brain. The company was formerly known as CBT Pharmaceuticals, Inc. and changed its name to Apollomics, Inc. in January 2019. Apollomics, Inc. was incorporated in 2015 and is based in Foster City, California.
989 East Hillsdale Blvd
Foster City, CA 94404
Foster City, CA 94404
CIK: 0001944885
ISIN: KYG0411D1079
:
